Introduction
Choroideremia is an X-linked recessive retinal degeneration that results in bilateral progressive loss of vision with onset typically in the second decade of life. 1 It is characterized by a degeneration of the retinal pigment epithelium (RPE), followed by the choriocapillaris and outer retina, 2 which slowly advances towards the posterior pole. Symptoms thus evolve from night blindness in the early stages to concentric field loss that encroaches on the macula over time, with central vision sometimes preserved until the seventh decade. 3 The disease has an estimated prevalence of 1 : 50 000. 4 Choroideremia is caused by a loss of function mutation in the CHM gene, which encodes the ubiquitously expressed 73.5 kDa RabGTPase escort protein 1 (REP1). RabGTPase (Rab) proteins are crucial for mediating the intracellular destination of transport vesicles 5 and in part, their trafficking specificity relies on prenylation by Rab geranylgeranyl transferase (RabGGTase), which requires REP1. The onset of severe visual loss from retinal degeneration may coincide with cataract formation, given the natural history of both conditions, prompting a patient enquiry regarding the safety and efficacy of cataract surgery. In addition, should gene therapy for choroideremia 6 become the future standard of care for selected patients, post-vitrectomy cataract 7, 8 will become more common. It is therefore important to establish whether choroideremia eyes are particularly vulnerable during and after cataract surgery. The small area of residual functioning retina, for example, may be susceptible to microscope light-induced phototoxicity or post-operative CMO. For this reason, we performed a detailed retrospective analysis of cataract surgery performed in choroideremia patients.
Materials and methods
Six patients with confirmed choroideremia who underwent uncomplicated cataract surgery in a single surgical unit between September 2011 and March 2014 were identified. They were recruited from a cohort of 65 patients seen at the Oxford Eye Hospital as part of an ongoing multi-centre UK-based gene therapy trial (www.clinicaltrials.gov, NCT01461213). However, none of these particular six patients had received gene therapy, as no trial patients have yet undergone cataract surgery. IRB approval (where relevant-for example, genetic testing) was covered by NCT01461213 and the study adhered to the tenets of the Declaration of Helsinki. Fundus autofluorescence, SD-OCT, and best-corrected Snellen visual acuity (VA) were recorded for all patients pre-operatively. The latter two tests were repeated post-operatively. Biometry was performed using laser interferometry with an IOL Master A-scan (Carl Zeiss Ltd, Cambridge, UK). Informed consent for standard cataract surgery was obtained from all patients. Exposure to potential retinal phototoxicity from the operating microscope was kept to a minimum throughout each case, as is routine for all patients with retinal degenerations in the study centre. Surgery was performed under topical anaesthesia with isotonic intracameral lignocaine in patients 2, 3, and 5; topical only in patients 4 and 6; and sub-tenons 50 : 50 mix of bupivicaine and lignocaine at a final concentration of 0.25 and 1%, respectively, with hyaluronidase 1500 IU in patient 1. An Infiniti phacoemulsification machine (Alcon Laboratories, Fort Worth, TX, USA) was used and post-operative topical steroid and broad-spectrum antibiotic were prescribed to the operated eye for 1 month in all cases. A paired Student's t-test was performed to compare mean central retinal thickness pre-and post-surgery.
Results
The visual acuities, demographic characteristics, and CHM gene mutations of each patient are shown in Table 1 . Five patients were of Caucasian background and a sixth was of Indian subcontinent descent. The median age (SD) was 54 (8) years, (range 49-70 years). All had advanced or end-stage retinal degeneration with no CMO. Cataract in patients 1 and 2 developed after 23 gauge pars plana vitrectomy and inner limiting membrane peel for full-thickness macular hole (FTMH) repair. Neither FTMH was associated with posterior retinal detachment, although this has been reported in choroideremia, 9, 10 and both achieved successful anatomical closure. Fundus imaging representative of the cohort is shown for patients 2 and 3 (see Figure 1) . A trace amount of pre-operative intraretinal cystic degenerative change was seen by SD-OCT in patient 4 only. Uncomplicated phacoemulsification was performed in all the six patients with placement of an intra-ocular lens (IOL) in the capsular bag. In view of the possibility of patients becoming entirely dependent on intrinsically photosensitive retinal ganglion cells (ipRGC) for their circadian function, blue light lenses were avoided because little is known about the effects of these lenses in patients with no photoreceptor function. Post-operative fundoscopic examination showed no sign of surgeryinduced CMO in any patient, which was confirmed by SD-OCT. There was no significant change in the median central retinal thickness (CRT), which was 163 mm (SD ¼ 79, range 79-273 mm) before surgery and 172 mm (SD ¼ 78, range 75-267 mm) at 1 month post surgery (P ¼ 0.95).
Patient 2 reported a subjective improvement in his VA although it remained at 'HM' post surgery. A thickened posterior capsule was noted intra-operatively and at 6 months, anterior capsularphimosis was evident with mild superior displacement of the IOL. Similarly, patient 1 noted some improvement in subjective acuity although objectively it remained 6/24. He developed early posterior capsular opacification, which required Nd:YAG laser capsulotomy. Patient 3 noted a slight improvement in VA in the operated eye for 1-2 days before a return to pre-operative levels. He described being able to see 'fingers moving', after being only 'light perception' before the operation. Unfortunately this was not sustained. He also described significant photophobia during the first week. Similarly, Patient 4 noticed a transient improvement in his VA for 3 days before it became more varied. It was subjectively better in the mornings. He developed significant early anterior 
Discussion
It is important to document that cataract surgery is safe in eyes with choroideremia given its potential to optimize vision in the late stages of the disease as senile cataract develops. In addition, iatrogenic cataract secondary to vitrectomy may become more frequent in choroideremia patients with the introduction of subretinal gene therapy, which currently requires removal of the vitreous to access the submacular space. To our knowledge this is the first published series of cataract surgery in choroideremia. Potential surgical risk factors in these eyes might include (i) higher rate of postoperative CMO; (ii) retinal phototoxicity from the operating microscope; (iii) weak zonules; or (iv) higher rates of post-operative capsular fibrosis. Although only a small series, this study suggests that cataract surgery in choroideremia carries no specific additional risk of intraor early post-operative complications, although early capsularphimosis may be a feature.
There have been a small number of retrospective studies examining cataract surgery in other heritable retinal degenerations such as retinitis pigmentosa and Usher syndrome, which showed that these patients generally had good outcomes. 11, 12 A retrospective analysis of 142 eyes of 89 patients with retinitis pigmentosa 13 reported a 14% rate of post-operative CMO as detected by fluorescein angiography. This compared with rates detected by SD-OCT in normal eyes after cataract surgery of between 4 and 11%. 14, 15 Although CMO is a recognized late complication of choroideremia itself, 16 no patients in this cohort developed postoperative CMO. 
Eye
Two patients developed anterior capsularphimosis (patients 2 and 4) and another (patient 1) required Nd:YAG laser capsulotomy for posterior capsular opacification, although no eyes exhibited significant zonular laxity. By comparison, aggressive capsularphimosis, zonular weakness and IOL dislocation have all been reported in retinitis pigmentosa. 13, [17] [18] [19] [20] [21] [22] [23] Phototoxicity is a serious consideration in the context of attenuated photoreceptor and RPE function as seen in choroideremia. The main risk factor for phototoxicity is the duration of surgery, 24, 25 which was kept to a minimum in all the patients and the eye was shielded from the microscope light during the pauses in operating. There was no subjective or objective evidence of retinal phototoxicity in this cohort.
An interesting observation was the transient subjective improvement in VA noted by patients 3 and 4 immediately after their surgery. One might speculate that this signalled an element of reversibility to the chorioretinal degeneration, if only short-lived, that was somehow induced by the cataract surgery. However, the early deterioration seen in patient 4 may have been due to a new vitreous floater obscuring the small central island of functional retina (with later exacerbation by anterior capsularphimosis). Improvement in choroideremia is not without precedent: in a phase 1 trial sustained improvement of 13 letters was noticed in a patient with choroideremia 24 weeks after the implantation of intravitreal encapsulated ciliary neurotrophic factor, 26 which perhaps boosted visual function in cells that had not yet undergone irreversible degeneration. In this study, the mechanism by which cataract surgery leads to transient improvement was unclear, but a transient surgeryinduced elevation in the intra-ocular growth factors is one possible mechanism. This is possible as some purified lens proteins, for example, b-and g-crystallin have been shown to stimulate the release of neuroprotective factors such as ciliary neurotropic factor (CNTF) in animal models. 27 In conclusion, this retrospective surgical case series has shown that for routine cataract surgery, potential choroideremia-specific sight-threatening complications such as retinal phototoxicity or CMO did not eventuate, although capsule-related changes were noted. None of the patients lost vision as a result of cataract surgery and all but one patient had an objective or subjective improvement in visual acuity, although maintenance of these gains may be limited by progression of retinal degeneration. We would recommend proceeding with cataract surgery in patients with choroideremia and visually significant cataract after discussing the guarded prognosis for improvement in VA as part of the consent process.
Summary
What was known before K Safety of cataract surgery in choroideremia eyes has not been previously published.
K Important to document whether choroideremia eyes are vulnerable to particular specific complications.
What this study adds
K No specific intra-or post-operative complications to which choroideremia eyes might be predisposed were observed in this series, for example, light microscopeinduced retinal phototoxicity or post-operative cystoid macular oedema.
K However, three eyes developed early capsular fibrosis. K The visual outcome was limited by the extent of chorioretinal degeneration.
K On the basis of these data, cataract surgery with a guarded prognosis for visual improvement is recommended in choroideremia eyes with visually significant cataract.
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